Baxalta sues Chugai for haemophilia drug patent breach
Baxalta has taken Chugai Pharmaceuticals to the Tokyo district court, claiming that the Japanese company has infringed upon its patent rights with their new haemophilia drug candidate, emicizumab (ACE910).
Emicizumab is currently in late stage trials for the treatment of haemophilia A. The study, co-sponsored by Roche, has set the number of bleeds over time to be the primary endpoint of the trial, which is set to be completed by January 2018.
Baxalta claims that the drug infringes upon one of its patents (patent number 4313531) and has filed an injunction against manufacture, usage, transfer, exportation, and offer of any transfer regarding emicizumab, and requested cessation.
The company has indicated that the manufacture and usage of emicizumab in clinical trials infringes its patent, and also pointed out its future commercial potential.
In a statement, Chugai has indicated its “confidence” that emicizumab does not infringe upon Baxalta’s patent and will “vigorously pursue [its] defence” in court. No changes are expected to be made to the financial prospects for the year 2016.
Global biotechnology company BioMarin Pharmaceuticals has announced that the US Food and Drug Administration (FDA) …
uniQure has announced that it has entered a definitive agreement to sell a portion of …